This week, the White House has been signaling that it sees progress on the problem of high drug prices, a subject of such concern to the administration that it released the “American Patients First” blueprint for reducing drug prices in 2018. However, some groups are calling for redoubled efforts on encouraging biosimilars as a way to generate savings and relieve the burden of high drug costs on the healthcare system and on patients.
This week, the White House has been signaling that it sees progress on the problem of high drug prices, a subject of such concern to the administration that it released the “American Patients First” blueprint for reducing drug prices in 2018.
In remarks delivered on Thursday during the signing of an executive order on Medicare, President Donald Trump said that he was “lowering the cost of prescription drugs, taking on the pharmaceutical companies,” even suggesting that impeachment attempts may have “come from some of the people that we’re taking on.”
Additionally, in a report issued this week, the White House Council of Economic Advisors touted progress on drug prices. According to the report, the Bureau of Labor Statistics’ Consumer Price Prescription Drug Index (CPI-Rx) is the most appropriate tool to assess price changes. When using the CPI-Rx as its preferred measure, “not only are drug prices increasing more slowly than general price inflation; in the most recent period, drug prices have been decreasing. As of August 2019, the CPI-Rx has declined by 0.7 percent over the previous 12 months.”
The report makes the claim that “the measurements cited in the media” that show that drug prices are increasing—including a newly released AARP report that shows that drugs’ retail prices in 2017 were 2.1% above the general inflation rate—are misleading. In part, says the council, that’s because “what matters are the changes in the prices of the most commonly prescribed drugs,” not high-cost, less frequently prescribed therapies, and list prices are “a less meaningful measure” of drug prices.
Despite the administration’s claims of progress on drug prices, however, some groups are calling for redoubled efforts on encouraging biosimilars as a way to generate savings and relieve the burden of high drug costs on the healthcare system and on patients.
First, this week, conservative think tank the Pacific Research Institute (PRI) published an issue brief in which it said that if biosimilars are able to achieve a 25%, 50%, or 75% market share, the US could increase its current annual $240 million in biosimilar savings to $2418 million, $4681 million, or $6999 million, respectively. Individual US states stand to see substantial savings, too; the brief estimates that, given 75% market share for biosimilars, annual state savings could range from $5.86 million in Wyoming to $598.95 million in Florida.
“These estimated savings are conservative,” says the brief, noting that some biosimilars have reached 90% or greater market penetration in some European nations, and greater savings could also result if more biologic drug classes become open to competition.
Pointing to those numbers, biosimilar industry group the Biosimilars Forum said in a statement that “There is no question that we must create policies that increase biosimilar use should be part of any executive order to lower Medicare costs. By implementing solutions that increase biosimilar access—such as eliminating out-of-pocket costs (co-pays), increasing physician add-on payments and implementing a shared savings program—President Trump can quickly generate competition that will reduce the cost of prescription drugs for seniors and patients in Medicare Part B.”
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.